Business
Three kidneyintelX.dkd Clinical Integrations
Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026. Disclaimer*
About this update from Renalytix Plc
[{"type":"text","content":"\n\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nThree kidneyintelX.dkd Clinical Integrations\n \nLONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use.\n \nThe integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix.\n \nThese integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations.\n \nRenalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources.\n \nTempus AI Collaboration\n \nRenalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients.\n \nThe collaboration with Tempus will support the development of soluti...